Roche Holding AG / Adaptive Biotechnologies Corporation
2019 · Licensing/Option · $2.3B · Terminated
Announcement Sentiment
38
Skeptical
Genentech (Roche Group) entered a worldwide collaboration and license agreement with Adaptive Biotechnologies to develop, manufacture and commercialize novel neoantigen-directed T-cell therapies. Adaptive received $300M upfront and is eligible for more than $2B in development, regulatory and commercial milestones plus royalties. Agreement was later terminated in February 2026.